Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II First-in-human Trial Investigating Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Dry Powder Cisplatin Formulation for Inhalation to Treat Stage IV Non-small Cell Lung Cancer Patients

NCT06896890 is registered in ClinicalTrials.gov with Inhatarget Therapeutics as lead sponsor.

NCT NCT06896890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06896890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II First-in-human Trial Investigating Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Dry Powder Cisplatin Formulation for Inhalation to Treat Stage IV Non-small Cell Lung Cancer Patients
Lead sponsor
Inhatarget Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 23, 2023
Completion date
October 1, 2026
Enrollment
32 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (advanced non-small cell lung cancer), stage iv lung cancer